Opinion/decision on a Paediatric investigation plan (PIP): Brukinsa, zanubrutinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0226/2024

EMEA-003613-PIP01-24

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised

EMEA-003611-PIP01-24

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 26, Status: Authorised

EMEA-003606-PIP01-24

Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised

EMEA-003605-PIP01-24

EMEA-003600-PIP01-24

Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 5, Status: Authorised